Freedom from disease activity in multiple sclerosis
- 27 April 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 74 (17_supplem), S3-S7
- https://doi.org/10.1212/wnl.0b013e3181dbb51c
Abstract
Background: Multiple sclerosis (MS) shares many pathologic features with other immune-mediated inflammatory diseases, such as rheumatoid arthritis, Crohn disease, and psoriasis. The development of effective biologic agents for rheumatoid arthritis has resulted in a treatment paradigm shift such that disease remission is now an explicit goal. Expert Clinical Opinion: The traditional immunomodulatory disease-modifying therapies for MS (interferon beta and glatiramer acetate) delay disease progression and reduce activity on brain MRI to varying degrees; however, they have not been demonstrated to induce disease remission. Therefore, the concept of disease remission or freedom from disease activity in MS has received little attention from the neurology community. We discuss some potential definitions of disease remission in MS and whether freedom from disease activity can become an increasingly useful measure of therapeutic response. Future Directions: Future research should be directed at determining the long-term significance of freedom from disease activity during a short-term clinical trial in relapsing-remitting MS.Keywords
This publication has 26 references indexed in Scilit:
- Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgraduate Medical Journal, 2007
- IMMUNOLOGY OF MULTIPLE SCLEROSISAnnual Review of Immunology, 2005
- Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease‐modifying antirheumatic drugs: Five‐year experience from the FIN‐RACo studyArthritis & Rheumatism, 2004
- Axonal Transection in the Lesions of Multiple SclerosisThe New England Journal of Medicine, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- REMISSION IN A PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS. AMERICAN RHEUMATISM ASSOCIATION PRELIMINARY REMISSION CRITERIA IN RELATION TO THE DISEASE ACTIVITY SCORERheumatology, 1995
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994